Core Insights - The company has successfully launched over ten AI-driven real-world research (AI-RWS) projects targeting prevalent mental health disorders among Chinese youth and elderly patients, marking a significant step in its strategic positioning within the "AI + clinical research" sector in Hong Kong [1] Academic and Research System - The forum gathered 40 leading experts in pediatric, adolescent psychiatry, and elderly cognitive disorders, establishing a comprehensive research system that integrates AI-driven classification, personalized treatment optimization, dynamic efficacy and safety predictions, and early relapse risk warnings [2] Key Sector Layout and Focus Products - **Youth Mental Health Sector**: The company initiated an AI-RWS study covering over 10,000 patients across 30 institutions in 15 cities, focusing on a population of over 30 million affected individuals. The study involves the exploration of combined treatments using its new drug group, which includes various formulations [3] - **Elderly Dementia and BPSD Sector**: The "Star Plan" aims to create the largest real-world database for BPSD in China, targeting 100,000 patients over five years, focusing on non-drug interventions and combination therapies to provide critical data for innovative drug registration and post-market safety evaluations [3] - The core clinical research products include the unique formulation of "Xienka Microtablet" which is recommended for treating mild to moderate dementia and is designed to address swallowing difficulties while showing superior efficacy compared to similar products [4] Commercialization Path and Future Outlook - The company employs a diversified funding model involving collaboration with research hospitals, pharmaceutical companies, government projects, and insurance co-payments, with project values ranging from millions to billions [5] - Future strategies include focusing on AI-RWS research and the development of intelligent physician assistants, aiming to become a global leader in the field while accelerating the transition to AI-driven clinical research services [5]

Core Insights - China Medical Group (08225) successfully held the "AI-RWS Real World Research Summit" in Shanghai, launching over ten AI-driven real-world research projects targeting high-prevalence mental disorders among Chinese youth and behavioral and psychological symptoms in dementia, marking a significant step in the company's strategic layout in the "AI + Clinical Research" sector, further consolidating its industry-leading position [1] Academic and Research System - The forum gathered 40 authoritative experts in pediatric, adolescent psychiatry, and geriatric cognitive disorders, learning from institutions like Stanford University and Mayo Clinic, and referencing the latest evidence-based guidelines from JAMA Psychiatry 2024 to construct a comprehensive research system integrating AI smart classification, personalized treatment path optimization, dynamic efficacy and safety prediction, and early warning of relapse risk [2] Core Sector Layout and Key Products - **Youth Mental Disorders Sector**: The company initiated an AI-RWS study covering over 30 institutions in 15 cities nationwide, targeting over 10,000 patients, focusing on the treatment of over 30 million affected youth in China. The study includes the exploration of combined or sequential treatments involving new drugs such as Xixin A, Xixin E, Xixin L, Xixin A, Xixin S, and Xixin L, aiming to optimize research protocols and predict disease progression [3] - **Dementia and BPSD Sector**: The "Star Plan" aims to build the largest and longest-followed BPSD real-world database in China, planning to include 100,000 patients over five years, focusing on non-drug interventions and combination therapies, providing critical data for innovative drug registration and post-marketing safety evaluations [3] - The company has obtained exclusive clinical research rights for key products like Xienka micro-patch and Xienmei flash tablets, which are recommended for treating mild to moderate dementia [4] Commercialization Path and Future Outlook - The company employs a diversified funding model involving collaboration with research hospitals, pharmaceutical companies, government projects, and insurance co-payments, with individual projects valued from millions to billions [5] - Leveraging platforms like Hainan Boao and Hengqin, the company can reduce the duration of Phase IV clinical studies by over 30%, aligning research outcomes with national health strategies, thus benefiting from policy advantages [5] - The company aims to focus on AI-RWS research and the development of intelligent physician agents, with core layouts in the Xixin mental health brand, Xien neurological brand, and Baimin allergic reaction brand, aspiring to become a global leader in the field and accelerate the transition to AI-driven clinical research services for enhanced shareholder value [5]

中國醫療集團有限公司（「本公司」欣然宣佈，近日於上海成功舉辦"AI -RWS 真實世界研究 高峰論壇"，並集中啟動十餘項針對中國青少年精神障礙、老年癡呆伴行為和心理症狀（BPSD） 兩大高發精神神經疾病的 AI 驅動真實世界研究（AI-RWS）專案 ，標誌著本公司在港股"AI+臨床 研究"賽道戰略佈局邁出關鍵一步，進一步鞏固行業領先地位。 一、學術與研究體系 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完備性亦無 發表聲明，並表明不會就本公告全部或任何部份內容或因倚賴該等內容而引致之任何損失承擔任何責任。 China Health Group Inc. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 自願性公告之中國醫療集團之最新業務進展 本次論壇彙聚 40 位國內兒科、青少年精神醫學及老年認知障礙領域權威專家，並学习斯坦 福大學、梅奧醫學中心，參照《JAMA Psychiatry》2024 年最新循證指南，構建"AI 智能分型—個 性化治療路徑優化—療效與安全動態預測—復發風險早期預警"全週 ...